세계의 인플루엔자 진단 산업은 2023년에 9억 4,690만 달러 규모에 달하며, 2030년에는 16억 310만 달러에 급증할 것으로 예측되며, 예측 기간 중 CAGR은 7.9%입니다.
인플루엔자 분석 솔루션의 수요는 인플루엔자에 의해 악화되는 만성질환의 증가, 고령화 인구의 증가, 이 질병의 만연을 추적하기 위한 정부 구상의 증가 등의 결과로 급증할 것으로 추정됩니다. 감염에 대한 기술적으로 복잡한 진단 툴의 성장도 이 업계의 큰 추진력이 되고 있습니다.
주요 인사이트
2023년에는 검사 키트와 시약 카테고리가 60%의 시장 점유율을 차지했습니다.
이것은 이 질병이 현재보다 일반적이고, 조기진단에 대한 주목도가 현저하게 높아지고 있기 때문입니다.
2023년에는 기존형 카테고리가 40%의 점유율로 업계를 선도했습니다.
이 카테고리에 속하는 인플루엔자 신속 진단 검사는 사용이 간단하고 결과가 빠르기 때문에 가장 높은 매출을 올렸습니다.
2023년에는 북미 지역이 판매 점유율의 65%를 차지했습니다만, 이것은 정부에 의한 광범위한 감시, TOP 기업의 존재, 기술적 개선에 의한 것입니다.
유럽연합(EU)은 인구 고령화가 진행되고 있으며, 2021년에는 5분의 1 이상이 65세 이상이 되는 것으로 인해 상당한 점유율을 차지할 것으로 예측됩니다.
세계의 인플루엔자 진단 시장을 분석했으며, 시장의 기본 구조·최신 상황 및 주요 촉진·억제요인, 세계 전체 및 지역별·주요 국가 시장 규모의 동향 전망(금액 기반, 2017-2030년), 제품별·검사 유형별·최종사용자별의 상세 동향, 현재의 시장 경쟁 상황, 주요 기업의 개요 등을 조사하여 전해드립니다.
목차
제1장 조사 범위
제2장 조사 방법
제3장 주요 요약
제4장 시장 지표
제5장 업계의 전망
시장 역학
동향
촉진요인
억제요인/과제
촉진요인/억제요인의 영향 분석
신종 코로나바이러스 감염증(COVID-19)의 영향
Porter's Five Forces 분석
제6장 세계 시장
개요
시장 매출 : 제품별(2017-2030년)
시장 매출 : 검사 유형별(2017-2030년)
기존형 진단 검사 시장의 매출 : 종류별(2017-2030년)
분자진단 검사 시장의 매출 : 종류별(2017-2030년)
시장 매출 : 최종사용자별(2017-2030년)
시장 매출 : 지역별(2017-2030년)
제7장 북미 시장
개요
시장 매출 : 제품별(2017-2030년)
시장 매출 : 검사 유형별(2017-2030년)
기존형 진단 검사 시장의 매출 : 종류별(2017-2030년)
분자진단 검사 시장의 매출 : 종류별(2017-2030년)
시장 매출 : 최종사용자별(2017-2030년)
시장 매출 : 국가별(2017-2030년)
제8장 유럽 시장
제9장 아시아태평양 시장
제10장 라틴아메리카 시장
제11장 중동 및 아프리카 시장
제12장 미국 시장
개요
시장 매출 : 제품별(2017-2030년)
시장 매출 : 검사 유형별(2017-2030년)
기존형 진단 검사 시장의 매출 : 종류별(2017-2030년)
분자진단 검사 시장의 매출 : 종류별(2017-2030년)
시장 매출 : 최종사용자별(2017-2030년)
제13장 캐나다 시장
제14장 독일 시장
제15장 프랑스 시장
제16장 영국 시장
제17장 이탈리아 시장
제18장 스페인 시장
제19장 일본 시장
제20장 중국 시장
제21장 인도 시장
제22장 호주 시장
제23장 한국 시장
제24장 브라질 시장
제25장 멕시코 시장
제26장 사우디아라비아 시장
제27장 남아프리카공화국 시장
제28장 아랍에미리트(UAE) 시장
제29장 경쟁 구도
시장 참여 기업과 제공 제품/서비스 리스트
주요 기업의 경쟁 벤치마킹
주요 기업의 제품 벤치마킹
최근 전략 개발 상황
제30장 기업 개요
3M Company
Abbott Laboratories Inc.
Becton, Dickinson and Company
Meridian Bioscience Inc.
QuidelOrtho Corporation
F. Hoffmann-La Roche Ltd.
SA Scientific Ltd.
Sekisui Diagnostics LLC
Thermo Fisher Scientific Inc.
Hologic Inc.
제31장 부록
KSA
영문 목차
영문목차
Market Overview
The worldwide influenza diagnostics industry generated USD 946.9 million in 2023, which is projected to surge to USD 1,603.1 million by 2030, experiencing a 7.9% CAGR during the projection period.
The requirement for influenza analysis solutions is estimated to surge as a outcome of the growing occurrence of chronic illnesses, several of which are deteriorated by the flu; rising aged populace, and growing government initiatives to track the spread of this illness. The growth of technically complex diagnostic tools for contamination is another major propeller for the industry.
An outbreak of flu can also be a global issue. As a result, huge amounts of R&D initiatives are launched for detection and drug improvement. In the majority of cases, the main research focus is the production of tests that can give fast and precise results on flu viruses in the quickest amount of time.
In 2019, the Centres for Collaborative Research on Influenza Vaccine Innovations (CIVICS) program, which is administered by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), was established to finance a variety of research initiatives pertaining to influenza epidemiology. Generously by NIAID (NIMB), the budgeted amount was USD 51 million emerged as the result of the first year of CIVIC's (Center for Integration of Veterans into the Civic Community) launch.
Key Insights
In 2023, the Test kits and reagent category held a leading market share of 60%.
This is due to the fact that these ailments are currently more common and with a notable rising attention towards early diagnosis.
However, points like ease of access without the necessity of writing a prescription (readily available on the market through pharmacies, retail stores, and online channels), ease of use, quick effect towards weight loss results, and affordable costs result in the growth of this category.
Together with the practical over-the-kit tests, the flu spread can be stopped because the isolated testing can be done without any contact with a suspected carrier.
Point-of-care testing allows people to economize by sending for professionals who are called in to conduct the tests. They also enjoy the tests being easy to conduct by themselves.
In 2023, the traditional category led the industry with a share of 40%.
The category is projected to experience a higher CAGR over the projection period.
Rapid influenza diagnostic tests within this category generated the highest revenue because of their simple use and fast results.
Augmented need for patient handling and surveillance testing for contagions in clinical settings.
Numerous RIDTs are accepted for use at houses and offices, with sanction from CLIA for usage in point-of-care services.
In 2023, the North American region held 65% of the revenue share, because of wide government surveillance, the existence of top companies, and technical improvements.
Well-recognized healthcare infrastructure and helpful reimbursement guidelines propel industry development.
European Union is projected to have a substantial share because of its aging populace, with more than one-fifth being 65 years or more in 2021.
Surging the possibility of flu in elders has led to WHO's recommendation of vaccinating senior people.
Table of Contents
Chapter 1. Research Scope
1.1. Research Objectives
1.2. Market Definition
1.3. Analysis Period
1.4. Market Size Breakdown by Segments
1.4.1. Market size breakdown, by product
1.4.2. Market size breakdown, by test type
1.4.3. Market size breakdown, by end user
1.4.4. Market size breakdown, by region
1.4.5. Market size breakdown, by country
1.5. Market Data Reporting Unit
1.5.1. Value
1.6. Key Stakeholders
Chapter 2. Research Methodology
2.1. Secondary Research
2.1.1. Paid
2.1.2. Unpaid
2.1.3. P&S Intelligence database
2.2. Primary Research
2.3. Market Size Estimation
2.4. Data Triangulation
2.5. Currency Conversion Rates
2.6. Assumptions for the Study
2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Market Indicators
Chapter 5. Industry Outlook
5.1. Market Dynamics
5.1.1. Trends
5.1.2. Drivers
5.1.3. Restraints/challenges
5.1.4. Impact analysis of drivers/restraints
5.2. Impact of COVID-19
5.3. Porter's Five Forces Analysis
5.3.1. Bargaining power of buyers
5.3.2. Bargaining power of suppliers
5.3.3. Threat of new entrants
5.3.4. Intensity of rivalry
5.3.5. Threat of substitutes
Chapter 6. Global Market
6.1. Overview
6.2. Market Revenue, by Product (2017-2030)
6.3. Market Revenue, by Test Type (2017-2030)
6.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
6.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
6.4. Market Revenue, by End User (2017-2030)
6.5. Market Revenue, by Region (2017-2030)
Chapter 7. North America Market
7.1. Overview
7.2. Market Revenue, by Product (2017-2030)
7.3. Market Revenue, by Test Type (2017-2030)
7.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
7.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
7.4. Market Revenue, by End User (2017-2030)
7.5. Market Revenue, by Country (2017-2030)
Chapter 8. Europe Market
8.1. Overview
8.2. Market Revenue, by Product (2017-2030)
8.3. Market Revenue, by Test Type (2017-2030)
8.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
8.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
8.4. Market Revenue, by End User (2017-2030)
8.5. Market Revenue, by Country (2017-2030)
Chapter 9. APAC Market
9.1. Overview
9.2. Market Revenue, by Product (2017-2030)
9.3. Market Revenue, by Test Type (2017-2030)
9.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
9.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
9.4. Market Revenue, by End User (2017-2030)
9.5. Market Revenue, by Country (2017-2030)
Chapter 10. LATAM Market
10.1. Overview
10.2. Market Revenue, by Product (2017-2030)
10.3. Market Revenue, by Test Type (2017-2030)
10.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
10.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
10.4. Market Revenue, by End User (2017-2030)
10.5. Market Revenue, by Country (2017-2030)
Chapter 11. MEA Market
11.1. Overview
11.2. Market Revenue, by Product (2017-2030)
11.3. Market Revenue, by Test Type (2017-2030)
11.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
11.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
11.4. Market Revenue, by End User (2017-2030)
11.5. Market Revenue, by Country (2017-2030)
Chapter 12. U.S. Market
12.1. Overview
12.2. Market Revenue, by Product (2017-2030)
12.3. Market Revenue, by Test Type (2017-2030)
12.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
12.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
12.4. Market Revenue, by End User (2017-2030)
Chapter 13. Canada Market
13.1. Overview
13.2. Market Revenue, by Product (2017-2030)
13.3. Market Revenue, by Test Type (2017-2030)
13.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
13.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
13.4. Market Revenue, by End User (2017-2030)
Chapter 14. Germany Market
14.1. Overview
14.2. Market Revenue, by Product (2017-2030)
14.3. Market Revenue, by Test Type (2017-2030)
14.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
14.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
14.4. Market Revenue, by End User (2017-2030)
Chapter 15. France Market
15.1. Overview
15.2. Market Revenue, by Product (2017-2030)
15.3. Market Revenue, by Test Type (2017-2030)
15.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
15.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
15.4. Market Revenue, by End User (2017-2030)
Chapter 16. U.K. Market
16.1. Overview
16.2. Market Revenue, by Product (2017-2030)
16.3. Market Revenue, by Test Type (2017-2030)
16.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
16.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
16.4. Market Revenue, by End User (2017-2030)
Chapter 17. Italy Market
17.1. Overview
17.2. Market Revenue, by Product (2017-2030)
17.3. Market Revenue, by Test Type (2017-2030)
17.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
17.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
17.4. Market Revenue, by End User (2017-2030)
Chapter 18. Spain Market
18.1. Overview
18.2. Market Revenue, by Product (2017-2030)
18.3. Market Revenue, by Test Type (2017-2030)
18.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
18.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
18.4. Market Revenue, by End User (2017-2030)
Chapter 19. Japan Market
19.1. Overview
19.2. Market Revenue, by Product (2017-2030)
19.3. Market Revenue, by Test Type (2017-2030)
19.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
19.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
19.4. Market Revenue, by End User (2017-2030)
Chapter 20. China Market
20.1. Overview
20.2. Market Revenue, by Product (2017-2030)
20.3. Market Revenue, by Test Type (2017-2030)
20.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
20.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
20.4. Market Revenue, by End User (2017-2030)
Chapter 21. India Market
21.1. Overview
21.2. Market Revenue, by Product (2017-2030)
21.3. Market Revenue, by Test Type (2017-2030)
21.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
21.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
21.4. Market Revenue, by End User (2017-2030)
Chapter 22. Australia Market
22.1. Overview
22.2. Market Revenue, by Product (2017-2030)
22.3. Market Revenue, by Test Type (2017-2030)
22.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
22.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
22.4. Market Revenue, by End User (2017-2030)
Chapter 23. South Korea Market
23.1. Overview
23.2. Market Revenue, by Product (2017-2030)
23.3. Market Revenue, by Test Type (2017-2030)
23.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
23.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
23.4. Market Revenue, by End User (2017-2030)
Chapter 24. Brazil Market
24.1. Overview
24.2. Market Revenue, by Product (2017-2030)
24.3. Market Revenue, by Test Type (2017-2030)
24.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
24.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
24.4. Market Revenue, by End User (2017-2030)
Chapter 25. Mexico Market
25.1. Overview
25.2. Market Revenue, by Product (2017-2030)
25.3. Market Revenue, by Test Type (2017-2030)
25.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
25.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
25.4. Market Revenue, by End User (2017-2030)
Chapter 26. Saudi Arabia Market
26.1. Overview
26.2. Market Revenue, by Product (2017-2030)
26.3. Market Revenue, by Test Type (2017-2030)
26.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
26.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
26.4. Market Revenue, by End User (2017-2030)
Chapter 27. South Africa Market
27.1. Overview
27.2. Market Revenue, by Product (2017-2030)
27.3. Market Revenue, by Test Type (2017-2030)
27.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
27.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
27.4. Market Revenue, by End User (2017-2030)
Chapter 28. U.A.E. Market
28.1. Overview
28.2. Market Revenue, by Product (2017-2030)
28.3. Market Revenue, by Test Type (2017-2030)
28.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
28.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
